BIOF BLUE BIOFUELS, INC.
Industrial Organic Chemicals · OTC · SEC CIK 1549145 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-21.1%
TTM EPS YoY-18.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-288.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets436.2%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-187.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.31M | $2.33M | $1.85M | $2.35M | $1.10M |
| SG&A expense | $1.41M | $1.73M | $1.34M | $1.54M | $1.03M |
| Operating income | -$3.72M | -$4.06M | -$3.19M | -$3.93M | -$2.17M |
| Net income | -$2.87M | -$1.42M | -$3.06M | -$3.96M | -$2.14M |
| EBITDA | -$3.57M | -$3.94M | -$3.07M | -$3.79M | -$2.04M |
| EPS (basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | — | — |
| Weighted avg. shares (diluted) | 312.19M | 303.85M | 299.95M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $65,200 | $48,797 | $41,008 | $211,901 | $1.16M |
| Current assets | $76,751 | $81,286 | $76,758 | $255,020 | $1.21M |
| PP&E, net | $555,109 | $539,648 | $587,308 | $420,115 | $377,645 |
| Intangibles | $61,098 | — | — | — | — |
| Total assets | $1.41M | $1.39M | $1.03M | $1.11M | $1.84M |
| Current liabilities | $2.98M | $2.21M | $1.50M | $638,721 | $496,161 |
| Total liabilities | $5.11M | $4.24M | $4.59M | $3.46M | $3.23M |
| Shareholders' equity | -$3.71M | -$2.85M | -$3.56M | -$2.36M | -$1.40M |
| Shares outstanding | 317.87M | 307.96M | 302.75M | 289.94M | 274.00M |
| Cash flow statement | |||||
| Operating cash flow | -$845,002 | -$1.00M | -$1.60M | -$2.04M | -$2.47M |
| Capital expenditure | $68,898 | $71,138 | $287,828 | $138,170 | $216,390 |
| Free cash flow | -$913,900 | -$1.07M | -$1.89M | -$2.17M | -$2.68M |
| Investing cash flow | -$137,345 | -$115,791 | -$320,505 | -$205,520 | -$233,132 |
| Financing cash flow | $998,750 | $1.13M | $1.75M | $1.29M | $3.58M |
| Depreciation & amortization | $145,852 | $118,798 | $119,476 | $138,464 | $131,715 |
| Stock-based compensation | $956,610 | $1.65M | $637,028 | $136,550 | $120,152 |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.